Lisa DeFrancesco
CIK 1846325 · SVP, IR and Corp Comm · last filed 2026-03-03
Lisa DeFrancesco is a SVP, IR and Corp Comm who has filed 7 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for LXRX, was dated Mar 3, 2026. Current disclosed insider exposure totals $180.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$180.2K
2
7
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LXRX | SVP, IR and Corp Comm | 93,869 | $1.92 | $180.2K | $0 | 4 | 2026-03-03 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | SVP, IR & Corp. Affairs | 10,308 | $19.00 | $195.9K | $0 | 3 | 2022-01-04 |
Recent Filings
7 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-03 | LXRX | Mixed | +78,292 | -$109.6K | EDGAR |
| 2026-02-17 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2025-03-03 | LXRX | Mixed | +15,577 | -$6.1K | EDGAR |
| 2025-02-18 | LXRX | Grant (A) | — | $0 | EDGAR |
| 2022-01-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −542 | -$8.8K | EDGAR |
| 2021-10-04 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −204 | -$3.0K | EDGAR |
| 2021-09-03 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Tax (F) | −538 | -$8.1K | EDGAR |